Clinical trial
A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)
NCT00280696 is registered in ClinicalTrials.gov with UCB Japan Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)
- Lead sponsor
- UCB Japan Co. Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- November 30, 2007
- Enrollment
- 352 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.